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Abstract 
Aims. The LION‐HEART study was a multicentre, double‐blind, randomised, parallel‐group, placebo‐controlled trial 
evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients 
with advanced chronic heart failure.  
Methods and results. Sixty‐nine patients from 12 centres were randomly assigned at a 2:1 ratio to levosimendan or 
placebo groups, receiving treatment by a 6‐hour intravenous infusion (0.2 μg/kg/min without bolus) every 2 weeks 
for 12 weeks. The primary endpoint was the effect on serum concentrations of N‐terminal pro‐B‐type natriuretic 
peptide (NT‐proBNP) throughout the treatment period in comparison with placebo. Secondary endpoints included 
evaluation of safety, clinical events and health‐related quality of life (HRQoL). The area under the curve (AUC, 
pg.day/mL) of the levels of NT‐proBNP over time for patients who received levosimendan was significantly lower 
than for the placebo group (344 × 103 [95% Confidence Interval (CI) 283 × 103−404 × 103] vs. 535 × 103 [443 × 
103−626 × 103], p = 0.003). In comparison with the placebo group, the patients on levosimendan experienced a 
reduction in the rate of heart failure hospitalisation (hazard ratio 0.25; 95% CI 0.11–0.56; P = 0.001). Patients on 
levosimendan were less likely to experience a clinically significant decline in HRQoL over time (P = 0.022). Adverse 
event rates were similar in the two treatment groups.  
Conclusions. In this small pilot study, intermittent administration of levosimendan to ambulatory patients with 
advanced systolic heart failure reduced plasma concentrations of NT‐proBNP, worsening of HRQoL and 
hospitalisation for heart failure. The efficacy and safety of this intervention should be confirmed in larger trials.  
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Introduction 
Heart failure (HF) is a progressive condition with a highly negative impact on the health care systems, 
and advanced HF represents a segment of patients with higher risk of death and hospitalisation and poorer 
health‐related quality of life (HRQoL).1-3 Advanced HF is defined by the presence of objective evidence 
of cardiac dysfunction, poor functional capacity, recurrent episodes of systemic and/or pulmonary 
congestion that translate into recurrent hospitalisations, impaired HRQoL and persistence of these 
features despite attempts to optimise therapy.
3  
 
Beyond the guideline‐recommended drug and device therapy, specific therapeutic options are limited 
and quite often fail to slow disease progression in many of these patients. The more complex advanced 
therapies such as long‐term mechanical circulatory support and/or heart transplant (HTx) are only 
available for a very limited number of patients with advanced HF. Thus, new therapeutic approaches 
capable of slowing down or preventing clinical progression and avoiding hospitalisation are an unmet 
need.
3,4 
 
The use of repetitive or continuous infusions of inotropic drugs to provide periods of intermittent 
haemodynamic relief in patients with advanced HF has been associated with improvements in symptoms 
and has been considered an attractive approach.
4
 However, data from several studies and meta‐analyses of 
randomised trials evaluating the safety and efficacy of beta‐adrenergic agonists and phosphodiesterase 
inhibitors in patients with HF suggest that this approach might not be safe.
5 
 
In contrast with other inotropes, the inodilator levosimendan promotes sensitization of the contractile 
apparatus to calcium ions without increasing the levels of intracellular calcium.
6
 Levosimendan has 
additional effects, mediated by its effect on the ATP‐dependent potassium channel at the vascular level, 
promoting vasodilatation, and at the mitochondrial level, promoting cardioprotection.
6,7
 Due to the 
pharmacological properties of levosimendan, its long‐lasting derived metabolites and its positive 
haemodynamic and cardioprotective effects, a pulsed or intermittent use of levosimendan has been 
suggested by some authors as an interesting therapeutic strategy in patients with advanced HF.
7,8 
 
Previous trials testing this strategy have been mostly open‐label, uncontrolled or single‐centre 
studies,
8
 and well‐designed randomised controlled trials have shown neutral results.9,10 Therefore, there 
are still uncertainties regarding the efficacy and safety of intermittent infusions of levosimendan and their 
potential impact on the outcomes in patients with advanced HF.  
 
Thus, the aim of our study was to evaluate the clinical impact of outpatient administration of 
intermittent intravenous infusions of levosimendan in patients with advanced HF. In this study, the 
primary endpoint of efficacy was the effect of ambulatory intravenous infusions of levosimendan 
compared to placebo, on the serum concentrations of N‐terminal pro‐B‐type natriuretic peptide (NT‐
proBNP) throughout the 12‐week treatment period. Secondary endpoints included safety, patient‐reported 
outcomes and clinical events.  
  
Methods 
The LION‐HEART study (Levosimendan® Intermittent administration in Outpatients: effects on 
Natriuretic peptides in advanced chronic HEART failure) was a multicentre, double‐blind, randomised, 
parallel‐group, placebo‐controlled trial evaluating the efficacy and safety of intravenous administration of 
intermittent doses of levosimendan in outpatients with advanced chronic HF.  
Study design and oversight 
Between November 2010 and December 2012, 69 patients fulfilling the inclusion criteria were 
enrolled from 12 recruiting centres in Spain (Figure 1 and Section H of the online supplementary 
Appendix). The study protocol was approved by the institutional review boards of each participating 
centre and conducted in accordance with the principles of the Declaration of Helsinki, International 
Conference on Harmonization Good Clinical Practice, and local and national regulations. All enrolled 
patients had provided written informed consent before any study‐related procedure was undertaken. 
Information on study investigators, committee members, registration and monitoring of the study is 
provided in Sections A–C of the online supplementary Appendix.  
 
 
 
Figure 1. Flow chart of screening, randomisation and follow‐up of the study 
 
  
Study population, eligibility and recruitment 
The study protocol and design are summarised in the supplementary material online, Figure S1. The 
main inclusion criteria were: age > 18 years, left ventricular ejection fraction <35% (measured in the 
previous 6 months) and clinical diagnosis of advanced chronic HF.
3
 A more detailed description of the 
study design, inclusion and exclusion criteria are provided in Section D of the online supplementary 
Appendix.  
Randomisation, blinding and therapy 
Eligible patients were randomised at a 2:1 ratio to receive either levosimendan or placebo. The 
placebo had the same appearance as levosimendan to ensure that the treatment was concealed from both 
the investigators and the study patients. Levosimendan or placebo was administered every 2 weeks by a 
6‐hour intravenous infusion (0.2 μg/kg/min, without bolus) for 12 weeks (6 cycles) in an ambulatory 
administration setting that allowed non‐invasive monitoring of vital signs. All measurements were taken 
prior to the infusion (pre‐infusion) and 24 hours after initiation if the infusion (post‐infusion). Additional 
key data on randomisation and therapy are provided in Section E of the online supplementary Appendix.  
Data collection and evaluation of the efficacy and safety endpoints 
Baseline information was obtained for stable patients, including the relevant clinical and demographic 
information. All the data including clinical events was re‐evaluated every 2 weeks for the first 3 months 
and every 4 weeks during the next 3 months.  
 
The primary endpoint of efficacy in the LION‐HEART study was the effect of 6 cycles of ambulatory 
6‐hour intravenous infusions of levosimendan every 2 weeks on the serum concentrations of NT‐proBNP 
throughout the 12‐week treatment period, in comparison with placebo. Measurements of NT‐proBNP 
levels were performed locally using an immunoassay based on chemiluminescence, employing the 
Elecsys® System (Roche Diagnostics, Rotkreuz, Switzerland). This method was used in all centres.  
 
Key secondary safety and efficacy objectives comprised functional variables, patient‐reported 
outcomes and clinical events including hospitalisation, death and other terminal events such as HTx and 
left ventricular assist device (LVAD) implant. Additional information on clinical data collection and other 
key aspects of safety and efficacy data are summarised in Section F of the online supplementary 
Appendix.  
Statistical analyses 
Data analysis was performed following an intention‐to‐treat strategy. For the primary efficacy 
analysis, a comparison of the area under the curve (AUC) of the NT‐proBNP values (expressed as 
pg.day/mL) throughout the treatment period (from the baseline visit 1 to visit 7 at week 12) and the pre–
post mean treatment difference was conducted, according to treatment allocation and taking into account 
patients who had died or were hospitalised at that time. Treatment groups were compared with respect to 
these primary endpoints using ANCOVA adjusted for baseline measurements and ANOVA, respectively.  
 
Repeated measures ANCOVA adjusted for baseline was used to compare treatment groups with 
respect to follow‐up NT‐proBNP values; the treatment‐by‐time interaction was examined in a sensitivity 
analysis. ANCOVA adjusted for baseline was also used to evaluate relative changes in NT‐proBNP from 
baseline to the end of the treatment period at week 12.  
  
Missing NT‐proBNP values were imputed using last observation carried forward for patients who 
were known to be alive and not hospitalised for that specific period. If a patient was hospitalised or had a 
terminal event, the highest preceding NT‐proBNP value for this particular patient was imputed.  
 
For the secondary efficacy and safety analyses, differences between treatments in the rate of 
occurrence of clinical endpoints were tested using Cox proportional hazards regression; hazard ratios 
(HR) and associated 95% confidence intervals (CI) estimated from the models are presented. Kaplan–
Meier survival curves comparing time to the first event by means of a log‐rank test for the composite 
event of all‐cause death or HF hospitalisation between both groups were also generated.  
 
The cumulative risk of HF hospitalisation taking all‐cause death into account as a competing risk was 
assessed using a Fine–Gray extension of the Cox regression model implemented in the cmprsk R 
package.
11
 Changes in continuous outcomes representing secondary efficacy and safety endpoints were 
analysed using repeated measures ANCOVA adjusted for baseline measurements.  
 
Additional information on statistical aspects of the study is provided in Section G of the online 
supplementary Appendix.  
 
All statistical tests and CI were constructed with a type I error level of 5% with no adjustments for 
multiplicity, and a P‐value of ≤0.05 was considered statistically significant. SPSS version 18.0 (IBM, 
Armonk, NY, USA) and the R software version 3.0.1 (R Foundation for Statistical Computing, Vienna, 
Austria) were used for statistical analyses.  
Results 
Baseline characteristics 
Baseline data of the patients are summarised in Table 1. Overall, 69 patients (48 receiving 
levosimendan and 21 placebo) were included in the study. Both groups were well balanced for most 
demographic data and clinical characteristics. However, the patients in the levosimendan group were 
older than in the placebo group [median (interquartile range) 70 (63–75) years vs. 66 (57–68) years, P = 
0.025] and tended to have better renal function than placebo patients [median (interquartile range) 
estimated glomerular filtration rate 55 (45–79) mL/min/1.73 m2 vs. 51 (43–56) mL/min/1.73 m2, P = 
0.095].  
Table 1. Demographics and baseline characteristics of the overall study population according to treatment group 
Variables Levosimendan (n = 48) Placebo (n = 21) 
   
Age, years 68 ± 10 63 ± 9 
Female gender 7 (15) 5 (24) 
BMI, kg/m2 27 ± 4 27 ± 5 
Systolic blood pressure, mmHg 114 ± 17 107 ± 10 
Heart rate, b.p.m. 73 ± 12 74 ± 13 
NYHA functional class   
III 46 (96) 19 (91) 
IV 2 (4) 2 (9) 
LVEF, % 27 ± 9 25 ± 6 
Ischaemic cause of HF 29 (60) 13 (62) 
Previous CV hospitalisation (1 year) 38 (79) 18 (86) 
Previous HF hospitalisation (1 year) 34 (71) 14 (67) 
Co‐morbidities   
Hypertension 32 (67) 13 (62) 
Atrial fibrillation 17 (35) 5 (24) 
Diabetes mellitus 24(50) 11 (52) 
Dyslipidaemia 27 (56) 14 (67) 
Anaemia 29 (66) 12 (60) 
Functional and PRO evaluation   
6MWT distance, m 284 ± 95 299 ± 86 
KCCQ overall summary score 47 ± 22 47 ± 22 
EQ‐5D VAS score 49 ± 19 50 ± 14 
Treatment   
ACEIs or ARBs 37 (77) 12 (57) 
Beta‐blockers 37 (77) 19 (91) 
MRAs 41 (85) 19 (91) 
Digoxin 21 (44) 11 (52) 
Diuretics 47 (98) 21 (100) 
Hydralazine–nitrate combination 2 (4) 1 (5) 
Antiplatelet therapy/anticoagulant 18 (38) 10 (48) 
ICD 29 (60) 15 (71) 
CRT 13 (27) 5 (24) 
Laboratory measurements   
Haemoglobin, g/dL 12.1 ± 2.3 12.8 ± 1.6 
Serum creatinine, mg/dL 1.3 ± 0.4 1.4 ± 0.3 
Serum creatinine, mg/dL 1.3 [1.0–1.4] 1.4 [1.2–1.6] 
eGFR, mL/min/1.73 m2 59 ± 21 49 ± 11 
Na, mEq/L 137 ± 5 136 ± 4 
K, mEq/L 4.3 ± 0.5 4.4 ± 0.6 
NT‐proBNP, pg/mL 5678 ± 4847 5419 ± 5331 
NT‐proBNP, pg/mL 4210 [2744–7095] 2770 [1736–7717] 
   
 
Data are expressed as mean ± standard deviation, as number (percentage), or as median [interquartile range].  
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CRT, cardiac 
resynchronisation therapy; CV, cardiovascular; eGFR, estimated glomerular filtration rate; EQ‐5D VAS, visual analogue scale of 
the Euro Quality of Life 5‐dimension instrument; ICD, implantable cardioverter‐defibrillator; K, potassium; KCCQ, Kansas City 
Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; 6MWT, 6‐minute walking test; MRA, mineralocorticoid 
receptor antagonist; Na, sodium; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; 
PRO, patient‐reported outcome.  
Administration of the study drug 
The number of patients who received each scheduled cycle is shown in Figure 1. A total of 61 patients 
(88%) received all the scheduled drug infusions. Cumulative mean levosimendan dose per patient was 
30.3 ± 8.9 mg [median: 31.5 mg (Q25–Q75: 27.2–35.3)].  
Primary outcome 
Primary endpoint analysis was performed evaluating 828 possible NT‐proBNP measurements. Among 
these, only 26 (3.1%) measurements were imputed. The baseline‐adjusted AUC of NT‐proBNP levels (in 
pg.day/mL) over time was significantly smaller in patients treated with levosimendan than in the placebo 
group [344 × 10,
3
 95% CI 283 × 10
3–404 × 103 vs. 535 × 10,3 95% CI 443 × 103–626 × 103; P = 0.003) 
(Figure 2A). When more stringent imputation rules were applied to missing assessments following 
terminal events, such as assigning the highest observed change from baseline over all patients for every 
missing assessment following a terminal event, similar results were observed.  
 
 
 
Figure 2. (A) Baseline‐adjusted mean N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) levels (pg/mL) and associated 95% 
confidence intervals (CI) by visit and treatment group. Comparison of the baseline‐adjusted area under the curve (AUC, in 
pg.day/mL) of NT‐proBNP levels by treatment group using ANCOVA test. Comparison of baseline‐adjusted NT‐proBNP (pg/mL) 
pre–post differences by treatment group using ANOVA test: pre–post mean difference placebo = 1320 pg/mL (95% CI 140; 2500); 
pre–post mean difference levosimendan = –1446 pg/mL (95% CI –222; –666) (P < 0.001). (B) Baseline‐adjusted relative 
(percentage) change in NT‐proBNP from baseline to the end of treatment, by treatment group [marginal means ± standard error of 
the mean (SEM)]  
  
The results based on AUC using log‐transformed values were also significant (P = 0.0185). The 
exclusion of one extreme value at visit 4 (week 7 of the study, 42 days after the first cycle) also yielded 
significant results (P = 0.0018). Furthermore, the unadjusted reduction in the NT‐proBNP levels from 
baseline to the end of treatment at week 12 was significantly greater in the levosimendan group than in 
the placebo group (P = 0.007) (Figure 2A).  
 
Analysis of repeated follow‐up NT‐proBNP values adjusted for baseline NT‐proBNP showed a 
significantly lower mean NT‐proBNP in the levosimendan group over the follow‐up period (P = 0.004).  
 
The addition of a treatment‐by‐time interaction to the model was statistically significant (P < 0.0001), 
consistent with a slight mean increase over time in the placebo group and a mean decrease in the 
levosimendan group (Figure 2A).  
 
The baseline‐adjusted mean change in NT‐proBNP from baseline to week 12 was 1320 (95% CI 140–
2500) pg/mL in the placebo group and –1446 (95% CI –222; –666) pg/mL in the levosimendan group (P 
< 0.001).  
 
Analyses with ANCOVA tests, when individual NT‐proBNP data were log‐transformed, showed 
similar results (P < 0.001). In sensitivity analyses of the primary endpoint including age and renal 
function as covariates, the results were consistent with the original models.  
 
The proportion of patients experiencing a clinically relevant reduction in NT‐proBNP levels (>25% 
from the baseline value) was significantly higher (P = 0.002, Fisher's exact test) in the levosimendan 
(48%) than in the placebo group (9%). Due to the low number of observations, we have included the P‐
values obtained with the Fisher's exact test. The mean percentage reduction in NT‐proBNP levels was 
also significantly greater in the levosimendan group (P < 0.001) (Figure 2B).  
Secondary outcomes 
The distribution of clinical events according to treatment allocation is shown in Table 2. During the 
study, 15 patients (31%) in the levosimendan group and 8 patients (38%) in the placebo group died (P = 
0.781). In the placebo group, two patients underwent HTx, and one received an LVAD implant, while this 
did not occur in the levosimendan group (P = 0.025). The rate of all terminal events (HTx, LVAD 
implant or death) was 48% (n = 10) in the placebo group and 31% (n = 15) in the levosimendan group (P 
= 0.303). The patients experienced 64 hospitalisations for any cause, 44 cardiovascular (CV) 
hospitalisations and 37 HF hospitalisations. Patients assigned to levosimendan experienced a significant 
reduction in the rate of HF hospitalisation (HR 0.25, 95% CI 0.11–0.56; P = 0.001) in comparison with 
the patients assigned to placebo (Table 2). The improvement in HF hospitalisation rate also translated into 
a significant reduction in CV hospitalisation, all‐cause hospitalisation and the composite endpoints 
between hospitalisation (all‐cause, CV or HF) and death or other terminal events (Table 2 and Figure 3). 
We also performed a competing‐risks regression analysis of HF hospitalisation, considering all‐cause 
death a competing event. In this analysis, and in agreement with the original results, levosimendan was 
associated with a significant reduction in the risk of HF hospitalisation throughout the study in 
comparison with placebo (HR 0.40, 95% CI 0.199–0.822; P = 0.012).  
Table 2. Clinical secondary pre‐specified endpoints according to treatment group 
 
Levosimendan (n = 48)  Placebo (n = 21)  
P‐
value* 
Hazard 
ratio 
(95% CI) 
P‐
value† 
 
Total 
events 
Patients with 
at least one 
event, n (%) 
Incidence per 
100 patient‐
years at risk 
 
Total 
events 
Patients with 
at least one 
event, n (%) 
Incidence per 
100 patient‐
years at risk 
 
   
            
Death or other terminal 
events 
           
All‐cause death 15 15 (31.2) 31.3  8 8 (38.1) 38.1  0.781 0.80 
(0.34–
1.90) 
0.620 
HTx 0 0 (0) 0.0  2 2 (9.5) 9.5  0.090 – – 
LVAD implant 0 0 (0) 0.0  1 1 (4.8) 4.8  0.304 – – 
Hospitalisation            
HF hospitalisation 19 11 (22.9) 22.9  18 14 (66.7) 66.7  0.001 0.25 
(0.11–
0.56) 
0.001 
CV hospitalisation 21 12 (25.0) 25.0  23 14 (66.7) 66.7  0.003 0.27 
(0.12–
0.59) 
0.001 
Non‐CV 
hospitalisation 
15 9 (18.8) 18.8  5 4 (19.0) 19.0  0.999 1.01 
(0.31–
3.27) 
0.990 
All‐cause 
hospitalisation 
36 17 (35.4) 35.4  28 15 (71.4) 71.4  0.012 0.37 
(0.19–
0.75) 
0.006 
Composite endpoints            
HF hospitalisation 
or all‐cause death 
34 22 (45.8) 29.2  26 17 (81.0) 66.7  0.015 0.33 
(0.16–
0.70) 
0.004 
CV hospitalisation 
or all‐cause death 
36 22 (45.8) 39.6  31 17 (81.0) 81.0  0.015 0.32 
(0.16–
0.61) 
0.001 
All‐cause 
hospitalisation or 
all‐ cause death 
51 25 (52.1) 45.8  36 18 (85.7) 85.7  0.017 0.38 
(0.20–
0.71) 
0.003 
HTx or LVAD 
implant 
0 0 (0) 0.0  3 3 (14.3) 14.3  0.025 – – 
HTx or LVAD or 
death 
15 15 (31.2) 31.3  11 10 (47.6) 47.6  0.303 0.55 
(0.25–
1.22) 
0.143 
HF hospitalisation 
or HTx or LVAD 
19 11 (22.9) 22.9  21 14 (66.7) 66.7  0.001 0.25 
(0.11–
0.55) 
0.001 
HF hospitalisation 
or HTx or LVAD 
or death 
34 22 (45.8) 41.7  29 17 (81.0) 81.0  0.015 0.34 
(0.17–
0.65) 
0.001 
CV hospitalisation 
or HTx or LVAD 
21 12 (25.0) 25.0  25 14 (66.7) 66.7  0.003 0.27 
(0.12–
0.58) 
0.001 
CV hospitalisation 
or HTx or LVAD 
or death 
36 22 (45.8) 41.7  33 17 (81.0) 81.0  0.015 0.33 
(0.17–
0.63) 
0.001 
            
 
CI, confidence interval; CV, cardiovascular; HF, heart failure; HTx, heart transplant; LVAD, left ventricular assist device.  
Comparison between both groups using *Kaplan–Meier (P‐value corresponds to a log‐rank test) and †Cox regression methods.  
 
 
 
Figure 3. Kaplan–Meier survival curves (time to the first event) for the composite event of all‐cause death or heart failure 
hospitalisation. P‐value according to log‐rank test  
Analysis of safety and tolerability is shown in Table 3 and in the online supplementary Table S1. 
Adverse events (AE) and serious adverse events (SAE) occurred in 57 (83%) and 51 (74%) of patients, 
respectively. However, drug‐related AE were observed only in 7 patients (10%). There were no 
significant differences between the assignment groups in terms of SAE, non‐serious AE or drug‐related 
AE. Interestingly, drug‐related SAE or AE leading to study drug withdrawal tended to be lower in the 
levosimendan group. The rate of patients needing an interim or permanent withdrawal of drug infusions 
did not differ between the two groups. The proportion of patients needing reduction or discontinuation of 
the infusion due to significant arterial hypotension (<80 mmHg or <100 mmHg with symptoms) was 
larger in the levosimendan than in the placebo group, but there were no statistically significant differences 
(Table 3 and online supplementary Figure S2). The ANCOVA tests for repeated measures, adjusted for 
baseline measurements, showed no significant difference in systolic blood pressure values between the 
two groups during the treatment period (P = 0.314; online supplementary Figure S3). Feasibility of drug 
administration is shown in the supplementary online Table S2. The number of patients who received the 6 
cycles of treatment was significantly higher (P = 0.044) in the levosimendan (45 patients, 94%) than in 
the placebo group (16 patients, 76%). 
  
Table 3. Description of adverse events and tolerability according to treatment group 
 
Levosimendan (n = 48) Placebo (n = 21) P‐value 
    
Safety, n (%)     
Any AE 37 (77.1) 20 (90.9) 0.204 
SAE 32 (66.7) 19 (86.4) 0.152 
Drug‐related AE 5 (10.4) 2 (9.1) 0.999 
Drug‐related SAE 3 (6.2) 2 (9.1) 0.646 
AE leading to drug withdrawal 2 (4.2) 4 (18.2) 0.073 
Tolerability, n (%)     
Temporary discontinuation of infusion 1 (2.1) 0 (0.0) 0.999 
Permanent discontinuation of infusion 5 (10.4) 3 (14.3) 0.692 
Reduction or discontinuation due to arterial hypotensiona 7 (14.9) 2 (9.5) 0.712 
    
 
AE, adverse event; SAE, serious adverse event. 
a Systolic blood pressure < 80 mmHg or <100 mmHg with symptoms.  
No differences were observed in heart rhythm parameters and rhythm disturbances between the two 
groups during the first cycle of administration of the study drug. In this period, new‐onset atrial 
fibrillations were not observed. Changes in the parameters of renal (estimated glomerular filtration rate, P 
= 0.226) and liver functions (alanine and aspartate transaminases, P = 0.583 and P = 0.202, respectively) 
were similar in the two groups.  
 
For the patient‐centred outcomes, adjusted analyses with the imputation of missing data did not show 
significant changes in New York Heart Association (NYHA) class (P = 0.841) or in EQ‐5D visual 
analogue scale (VAS) scores (P = 0.474) in the two groups throughout the study. However, in analyses 
without imputation and after 6 months of follow‐up, the patients on levosimendan were more likely to 
improve by at least one NYHA class (odds ratio 4.3, 95% CI 1.1–18.3; P = 0.042). They also were less 
likely to experience a clinically significant decline in HRQoL according to EQ‐5D VAS [5/24 
levosimendan patients (21%) vs. 7/11 placebo patients (63%), P = 0.022] (Figure 4).  
 
 
 
Figure 4. Proportion of patients reporting a clinically significant decline in their self‐reported quality of life at 6 months of follow‐
up, according to treatment group. A clinically significant decline was considered a reduction of 5 points (minimal clinically 
important difference) on the EQ‐5D visual analogue scale between the baseline and visit 10 (6 months)   
Discussion 
In the LION‐HEART study, treatment of 6 cycles of intermittent infusions of levosimendan 
administered to outpatients with advanced chronic HF significantly reduced NT‐proBNP levels (primary 
endpoint of the study) in comparison with placebo. This positive effect translated into clinical 
improvements: compared to the placebo group, the levosimendan patients experienced a significant 
reduction in the risk of hospitalisation, mainly driven by a significant reduction in HF‐related 
hospitalisations. Moreover, the composite endpoints including hospitalisation (all‐cause, CV or HF) and 
death or other terminal events were also significantly lower in the levosimendan group. Consistently with 
these findings, a significant decline in HRQoL over time was more common in placebo patients. 
Importantly, the safety and tolerability of levosimendan were similar to those of placebo. Although 
beneficial clinical effects of intermittent use of levosimendan in advanced HF have been previously 
suggested,
8-10
 our study is the first multicentre trial showing positive results in both primary (decrease in 
natriuretic peptide levels) and key secondary endpoints such as hospitalisation.  
 
These results could be explained by the haemodynamic and cardioprotective effects of 
levosimendan,
6,7
 which might improve left ventricular performance without increasing oxygen 
consumption.
12
 We could hypothesise that intermittent exposure to levosimendan provided short periods 
of haemodynamic relief. This might have caused a reduction in natriuretic peptide concentration and a 
decrease in the number of clinical events. Since previous studies have shown that 6‐hour infusions of a 
similar dose of levosimendan do not sustain the haemodynamic effect after 2 weeks,
13 
the intermittent 
episodes of haemodynamic relief cannot be the only explanation of our results. However, we might also 
hypothesise that an intermittent exposure to levosimendan slows the progression of the disease due to its 
cardioprotective effects. One might speculate that the preservation of cardiac function prevents new 
episodes of haemodynamic deterioration. This, in turn, would translate into a reduction in the number of 
HF‐related events and a relative preservation of HRQoL.14,15 
 
Despite some similarities between our study and the LevoRep study, the latter has failed to 
demonstrate a positive effect for its primary endpoint, although a positive trend for secondary clinical 
endpoints was reported
.9
 Several aspects related to the LevoRep study design might explain the 
differences between these two studies. In particular, the number of treatment cycles was larger in the 
LION‐HEART study (6 cycles) than in the LevoRep study (4 cycles). This resulted in a two‐fold increase 
in the mean cumulative dose of levosimendan per patient in our study (30.3 ± 8.9 mg) in comparison with 
the LevoRep results (14.3 ± 4.7 mg). The use of NT‐proBNP as the primary endpoint in our study was 
sustained by two main reasons. Firstly, natriuretic peptide levels are correlated with the haemodynamic 
status of the patients,
16
 and the changes in their levels mimic the changes in the overall cardiac 
performance in response to therapeutic interventions. For this reason, the changes in NT‐proBNP levels 
have also been used as primary endpoints in other studies.
17 
However, this biomarker has been reported as 
an imperfect surrogate of clinical events.
18
 Secondly, the LION‐HEART trial was designed as a proof‐of‐
concept study: we were testing the use of levosimendan with a dose, duration of infusion, interval 
between infusions and clinical setting (outpatients with advanced HF) that had not been tested before. 
Thus, demonstrating the proof‐of‐concept that this administration scheme would translate into a 
measurable biological effect was a key aspect of the study. In this regard, the evaluation of changes in the 
NT‐proBNP levels throughout the treatment using an AUC approach helped to define the biological 
impact of this therapeutic strategy (mitigation of the neurohormonal burden imposed by advanced HF) 
and correlate these changes with improved clinical outcomes.  
 
An additional important message of our study is that the administration of levosimendan following the 
regime proposed in the LION‐HEART is safe and well tolerated. No differences were found in adverse 
event rates, both serious and non‐serious, between the levosimendan and placebo groups. The proportion 
of deaths tended to be lower for the patients allocated to levosimendan than in the placebo group (31% vs. 
38%), although this trend was not statistically significant. This is in contrast with other studies of acute 
HF, where the administration of levosimendan was associated with a non‐significant increase in the 
number of fatal events in comparison with placebo.
18,19
 Excessive hypotension associated with the use of 
bolus of levosimendan might explain this difference.   
The treatment was well tolerated and, in fact, the proportion of patients that received the 6 cycles of 
treatment tended to be higher in the levosimendan group. Importantly, there were no differences between 
the percentages of patients in the two groups needing an interruption in the infusion procedure due to 
significant hypotension. A similar level of safety and tolerability has been reported in the LevoRep 
study.
9
 Based on that, the repetitive 6‐hour outpatient infusions of levosimendan in advanced HF seem to 
be a feasible approach. This is very important considering the limited available therapeutic options for 
such patients.  
Study limitations 
The LION‐HEART study was powered to evaluate the differences in NT‐proBNP levels between the 
two allocation groups over the treatment period. However, our study was not powered to evaluate the 
differences in clinical events, symptoms and patient‐reported outcomes. Given the calculated sample size, 
all these evaluations were planned as exploratory. However, the findings for these secondary endpoints 
were consistent with the results for the primary endpoint and were statistically significant despite the 
limited sample size. Although there were no safety signals, a much larger, adequately powered study is 
needed to ensure that levosimendan does not cause more hypotension, arrhythmias and mortality than the 
placebo and to confirm its effects on the clinical outcomes observed in the LION‐HEART study.  
Conclusions 
This exploratory pilot study demonstrated that an intermittent administration of levosimendan to 
ambulatory patients with advanced systolic HF was safe, significantly decreased the level of natriuretic 
peptides and was associated with clinical benefits. Larger studies are needed to confirm the safety and 
efficacy of this therapeutic strategy and its effect on clinical and patient‐reported outcomes.  
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